Valtech Cardio (Israel) a development-stage medical device company focused on minimally invasive percutaneous annuloplasty ring valve repair for the treatment of mitral valve regurgitation, closed a $17.8M Series B financing. Participants include OXO Capital, NGN Capital and Peregrine Ventures.